Gam Holding Ag Blueprint Medicines Corp Transaction History

Gam Holding Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 10, 2021	SELL	$92.08 - $124.48 $2.15 Million - $2.91 Million	-23,390 Closed	0 $0
Q2 2020 Aug 10, 2020	SELL	$57.09 - $79.27 $887,692 - $1.23 Million	-15,549 Reduced 39.93%	23,390 $1.82 Million
Q3 2019 Nov 08, 2019	SELL	$72.9 - $101.41 $503,010 - $699,729	-6,900 Reduced 15.05%	38,939 $2.86 Million
Q2 2019 Aug 12, 2019	SELL	$73.54 - $97.8 $220,620 - $293,400	-3,000 Reduced 6.14%	45,839 $4.32 Million
Q1 2019 May 10, 2019	SELL	$48.7 - $86.6 $567,890 - $1.01 Million	-11,661 Reduced 19.27%	48,839 $3.91 Million
Q4 2018 Feb 08, 2019	SELL	$45.57 - $74.26 $332,661 - $542,098	-7,300 Reduced 10.77%	60,500 $3.26 Million
Q3 2018 Nov 13, 2018	BUY	$58.91 - $78.32 $1.55 Million - $2.06 Million	26,300 Added 63.37%	67,800 $5.29 Million
Q2 2018 Aug 09, 2018	BUY	$60.96 - $101.18 $1.63 Million - $2.71 Million	26,800 Added 182.31%	41,500 $2.63 Million
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $1.08 Million - $1.51 Million	14,700 New	14,700 $1.35 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Gam Holding Ag, based on Form 13F filings with the SEC.

Stay updated on Gam Holding Ag with notifications on news.